Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comparison of protection against mpox following mRNA or modified vaccinia Ankara vaccination in nonhuman primates

4 Sept 2024

Abstract excerpt

In 2022, mpox virus (MPXV) spread worldwide, causing 99,581 mpox cases in 121 countries. Modified vaccinia Ankara (MVA) vaccine use reduced disease in at-risk populations but failed to deliver complete protection. Lag in manufacturing and distribution of MVA resulted in additional MPXV spread, with 12,000 reported cases in 2023 and an additional outbreak in Central Africa of clade I virus. These outbreaks...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bacillus and Francisella bacterial research
Share to Herpesvirus Infections and Treatments
Share to Poxvirus research and outbreaks

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39236707
DOI: 10.1016/j.cell.2024.08.043

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comparison of protection against mpox following mRNA or modified vaccinia Ankara vaccination in nonhuman primatesPMID 39236707Read ↗

An mpox virus mRNA-lipid nanoparticle vaccine confers protection against lethal orthopoxviral challengeSemantic proximity Read ↗

A monkeypox mRNA-lipid nanoparticle vaccine targeting virus binding, entry, and transmission drives protection against lethal orthopoxviral challengeSemantic proximity Read ↗

A multivalent mRNA monkeypox virus vaccine (BNT166) protects mice and macaques from orthopoxvirus diseaseSemantic proximity Read ↗

A multivalent mRNA vaccine elicits robust immune responses and confers protection in a murine model of monkeypox virus infectionSemantic proximity Read ↗

Mpox multiprotein virus-like nanoparticle vaccine induces neutralizing and protective antibodies in mice and non-human primatesSemantic proximity Read ↗

Mpox vaccine and infection-driven human immune signaturesSemantic proximity Read ↗

Immunological analysis of LC16m8 vaccine: preclinical and early clinical insights into mpoxSemantic proximity Read ↗

The unique immune evasion mechanisms of the mpox virus and their implication for developing new vaccines and immunotherapiesSemantic proximity Read ↗

Critical Appraisal of Mpox (Monkeypox) in Africa using Scoping and Systematic Reviews: Epidemiology, Biochemistry, Phylogeny, Pathogenesis, Clinical Features, Diagnosis, Treatment, Biosecurity and One-HealthSemantic proximity Read ↗

Real-world effectiveness of mpox (monkeypox) vaccines: a systematic reviewSemantic proximity Read ↗

Polyvalent mRNA vaccination elicited potent immune response to monkeypox surface antigensSemantic proximity Read ↗

Targeting Mpox: From Pharmacological Mechanisms to Next-Generation TherapiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.